Integer Holdings Corporation (NYSE:ITGR) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Integer Holdings Corporation to reach your target.
Based on historical returns, we believe that Integer Holdings Corporation can grow its free cash at a rate of about 3%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| ITGR Price (Integer Holdings Corporation stock price per share) |
$126.97 | |
|
|
ITGR Fair Price (based on intrinsic value) |
$51.38 |
| ITGR Safety Price (based on a variable margin of safety) | $30.83 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 110% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 0% lower than other Medical Devices stocks | |
| Free Cash Flow Jitter | 39% | |
No open-market insider buys or sells are recorded for the last 12 months.
Open-market buys and sells reported by Integer Holdings Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2024-05-24 | Hinrichs James F. | Sell | 9,603 | $122.44 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,432,036 shares shorted. With 28,900,796 shares available for purchase and an average trading volume over the past 10 trading days of 732,630, it would take at least 4.7 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 1114483 | 52.1 |
| 2010 | 1114483 | 59 |
| 2011 | 1114483 | 70.5 |
| 2012 | 1114483 | 40 |
| 2013 | 1114483 | 33.1 |
| 2014 | 1114483 | 56.6 |
| 2015 | 1114483 | -17.9 |
| 2016 | 1114483 | 67.9 |
| 2017 | 1114483 | 111 |
| 2018 | 1114483 | 123 |
| 2019 | 1114483 | 117 |
| 2020 | 1114483 | 132 |
| 2021 | 1114483 | 109 |
| 2022 | 1114483 | 62.8 |
| 2023 | 1114483 | 112 |
| 2024 | 1114483 | 125 |
| 2025 | 1114483 | 107 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 14 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,928 million against net income of $1,049 million, or 1.84 times. Net income was negative in 3 of the 17 years, and those years are left out of the ratio.
In 2025, operating cash flow was 1.91 times net income, compared with 2.52 times for the earliest three years (2009 to 2011).
In 2025, capital expenditures were $91 million, 46.4% of operating cash flow of $196 million, which leaves an estimated $105 million after capex. Across the 17 years with reported capex, it averaged 42.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
Cash conversion in 2025 was 1.91, at least 0.25 under the 2.52 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | -9 | 71.8 | 19.7 | n/a |
| 2010 | 33.1 | 76.9 | 16.1 | 2.32 |
| 2011 | 33.1 | 89.9 | 22.5 | 2.71 |
| 2012 | -4.8 | 64.8 | 41.1 | n/a |
| 2013 | 36.3 | 56.8 | 18.9 | 1.56 |
| 2014 | 55.5 | 81.3 | 24.8 | 1.47 |
| 2015 | -7.6 | 12.5 | 44.6 | n/a |
| 2016 | 6 | 106 | 58.6 | 17.70 |
| 2017 | 66.7 | 149 | 47.3 | 2.24 |
| 2018 | 168 | 167 | 44.9 | 1.00 |
| 2019 | 96.3 | 165 | 48.2 | 1.72 |
| 2020 | 77.3 | 181 | 46.8 | 2.35 |
| 2021 | 96.8 | 157 | 53.5 | 1.62 |
| 2022 | 66.4 | 116 | 74.7 | 1.75 |
| 2023 | 90.7 | 180 | 120 | 1.99 |
| 2024 | 120 | 205 | 105 | 1.71 |
| 2025 | 103 | 196 | 91 | 1.91 |
How to read this: earnings and margins.
Revenue was $522 million in 2009 and $1,854 million in 2025, a compound annual growth rate of 8.2% over 16 years.
Revenue rose 8.0% from 2024 to 2025.
Our estimated free cash flow was $107 million in 2025, 5.8% of revenue. In 2009 the estimated margin was 10.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 522 | 52.1 | 10.0% |
| 2010 | 533 | 59 | 11.1% |
| 2011 | 569 | 70.5 | 12.4% |
| 2012 | 646 | 40 | 6.2% |
| 2013 | 664 | 33.1 | 5.0% |
| 2014 | 688 | 56.6 | 8.2% |
| 2015 | 800 | -17.9 | -2.2% |
| 2016 | 1,387 | 67.9 | 4.9% |
| 2017 | 1,462 | 111 | 7.6% |
| 2018 | 1,215 | 123 | 10.1% |
| 2019 | 1,258 | 117 | 9.3% |
| 2020 | 1,073 | 132 | 12.3% |
| 2021 | 1,221 | 109 | 8.9% |
| 2022 | 1,331 | 62.8 | 4.7% |
| 2023 | 1,556 | 112 | 7.2% |
| 2024 | 1,717 | 125 | 7.3% |
| 2025 | 1,854 | 107 | 5.8% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $17.2 million against total liabilities of $1,664 million, or 1.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 48.8% of total assets in 2025, compared with 45.1% in 2010, an increase of 3.7 percentage points.
Stockholders equity was $1,747 million in 2025, compared with $427 million in 2010, a rise of 309.2%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.4% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 777 | 22.9 | 350 | 427 |
| 2011 | 881 | 36.5 | 414 | 467 |
| 2012 | 890 | 20.3 | 409 | 481 |
| 2013 | 890 | 35.5 | 349 | 542 |
| 2014 | 955 | 76.8 | 342 | 613 |
| 2015 | 2,982 | 82.5 | 2,132 | 851 |
| 2016 | 2,833 | 52.1 | 2,107 | 725 |
| 2017 | 2,848 | 44.1 | 1,955 | 893 |
| 2018 | 2,327 | 25.6 | 1,266 | 1,060 |
| 2019 | 2,353 | 13.5 | 1,201 | 1,152 |
| 2020 | 2,372 | 49.2 | 1,101 | 1,271 |
| 2021 | 2,582 | 17.9 | 1,228 | 1,355 |
| 2022 | 2,794 | 24.3 | 1,377 | 1,417 |
| 2023 | 2,943 | 23.7 | 1,424 | 1,519 |
| 2024 | 3,078 | 46.5 | 1,459 | 1,619 |
| 2025 | 3,411 | 17.2 | 1,664 | 1,747 |
Positive free cash flow appears in 16 of the 17 fiscal years we hold for Integer Holdings Corporation from its current SEC filer.
Free cash flow from the first three years of data averaged $60.5 million, and from the last three $115 million: a sharp rise.
Free cash flow is volatile from year to year, with a variability measure of 39%.
Integer Holdings Corporation is priced at $126.97, above our fair value estimate of $51.38 and its safe value of $30.83.
We do not have a dividend yield for Integer Holdings Corporation.
These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 110% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Devices industry, the ones closest in market capitalization to Integer Holdings Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Integer Holdings Corporation (ITGR) | 4,317 | 42.6 | - | - | 147% above |
| ICU Medical (ICUI) | 4,315 | 72.2 | - | 1.4% | 29% above |
| LivaNova PLC (LIVN) | 4,998 | 26.0 | - | - | 317% above |
| Merit Medical Systems (MMSI) | 5,053 | 31.6 | - | 1.1% | 117% above |
| Haemonetics Corporation (HAE) | 5,472 | 53.2 | - | 1.7% | 132% above |
| UFP Technologies (UFPT) | 2,253 | 29.7 | - | 0.1% | 395% above |
| Teleflex Incorporated (TFX) | 6,408 | 79.6 | 0.8% | 5.7% | 24% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1114483.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ITGR annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Integer Holdings Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ITGR: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market